Genetic insights in this article
- CYP3A4 metabolizer status affects how quickly BPC-157 clears from your system. Poor metabolizers may experience stronger effects at lower doses.
- CYP2D6 phenotype (poor, intermediate, normal, or ultra-rapid metabolizer) is the most well-studied pharmacogenomic variant — affecting over 25% of all prescription drugs.
- NOS3 gene variants determine your baseline nitric oxide production, which BPC-157 upregulates. Lower baseline NO may mean more pronounced vascular effects.
TL;DR
- 1.Standard BPC-157 dosing (250-500 mcg/day) is a population average — your genetics determine if it's right for you.
- 2.CYP3A4 metabolizer status is the biggest factor: poor metabolizers need lower doses, ultra-rapid metabolizers may need higher.
- 3.Always start with an assessment dose (150-200 mcg) for the first week, regardless of your target dose.
- 4.Oral BPC-157 has significantly lower bioavailability than injection — roughly double the dose needed.
- 5.If you're on prescription medications, CYP2D6 status matters for drug interaction risk — get tested first.
Search "BPC-157 dosage" and you'll find the same numbers repeated everywhere: 250-500 mcg per day, subcutaneous injection, 4-8 week cycles. These ranges come from animal study extrapolations and community consensus — not from clinical trials with pharmacokinetic data.
That doesn't mean those ranges are wrong. It means they're averages — and you may not be average. Your CYP enzyme metabolism, body composition, injury severity, and administration route all affect what dose actually works for you.
Imagine a shoe store that only sells size 10. It fits most people okay-ish, but it's not actually right for anyone with smaller or larger feet. Standard BPC-157 dosing is the size 10 shoe. Your CYP enzymes are your actual shoe size.
What is the standard BPC-157 dosage?
Before we get into genetics, here's what's commonly used in the peptide community and by practitioners:
| Route | Dose Range | Best For | Notes |
|---|---|---|---|
| SubQ (near injury) | 250-500 mcg/day | Localized tendon/joint repair | Most common. Inject close to injury site. |
| SubQ (systemic) | 250-500 mcg/day | Gut healing, systemic inflammation | Abdominal injection when injury site not accessible. |
| Oral (capsules) | 500-1000 mcg/day | Gut conditions (ulcers, IBD, NSAID damage) | Lower bioavailability — roughly 2x the injection dose needed. |
Some practitioners scale to body weight: roughly 3-10 mcg/kg/day. For an 80 kg person, that's 240-800 mcg/day — matching the standard range. Most protocols recommend 4-8 week cycles with 2-4 weeks off.
Why doesn't the same BPC-157 dose work for everyone?
Here's the problem with every dosing guide that gives you a flat number: pharmacokinetics are individual. The same dose of any compound produces different blood levels in different people. For prescription drugs, this is why pharmacogenomic testing exists. For peptides, most people are still guessing.
CYP3A4: Your Primary Clearance Enzyme
BPC-157 is processed through the CYP450 enzyme system. CYP3A4 is the most abundant CYP enzyme in your liver and intestines — it handles approximately 50% of all drugs you consume. Your CYP3A4 activity level directly affects how quickly BPC-157 is cleared from your body:
Of all drugs and compounds you consume are processed by a single enzyme: CYP3A4. Your genetic variant in this enzyme is the single biggest factor in how you respond to BPC-157.
- Normal metabolizers (~60% of population): Standard dosing ranges are appropriate.
- Poor metabolizers (~5-10%): BPC-157 lingers longer in your system. The standard dose may produce higher-than-expected tissue concentrations. Starting at the lower end (200-250 mcg) and titrating up makes sense.
- Ultra-rapid metabolizers (~5-15%): You clear BPC-157 faster than average. The standard dose may not achieve optimal tissue concentration. Some may benefit from the higher end of the range or split dosing (morning + evening).
CYP2D6: The Drug Interaction Factor
CYP2D6 is the most variable CYP enzyme in humans. While its direct role in BPC-157 metabolism is less established than CYP3A4, CYP2D6 status matters for a practical reason: drug interactions.
If you're taking SSRIs, beta-blockers, codeine, or any of the 25%+ of prescription drugs metabolized by CYP2D6, your metabolizer status determines whether adding BPC-157 to your protocol creates a pharmacokinetic bottleneck. Poor CYP2D6 metabolizers already have reduced clearance capacity — adding another compound that requires hepatic processing can amplify side effects of both the drug and the peptide.
NOS3 and Vascular Response
BPC-157's healing mechanism relies heavily on nitric oxide (NO) upregulation via the eNOS pathway. Your NOS3 gene variants (particularly rs1799983, the Glu298Asp polymorphism) affect your baseline NO production. People with reduced NOS3 activity may experience more pronounced vascular effects from BPC-157 at the same dose — including blood pressure changes, flushing, or headaches.
This doesn't mean you should avoid BPC-157. It means starting at a lower dose and monitoring your response is more important if you carry these variants.
BPC-157 widens your blood vessels through nitric oxide. If your NOS3 gene already keeps your blood vessels on the wider side, adding BPC-157 on top can cause lightheadedness or flushing — especially at higher doses. Starting low lets you find your comfortable range.
How should you approach BPC-157 dosing?
Instead of a flat "take 500 mcg," consider a phased approach:
Assessment — 150-200 mcg/day
Below the therapeutic range on purpose. You're testing tolerance: injection site reactions, vascular effects (lightheadedness, flushing), general response. If you're a poor CYP metabolizer or carry NOS3 variants, this conservative start is critical.
Titration — 250-300 mcg/day
If week 1 went smoothly, step up. Most people notice the first therapeutic effects here — reduced pain, improved tissue mobility, or gut symptom improvement. Pay attention to what changes.
Therapeutic — 250-500 mcg/day
Settle into your dose based on response. Where you land depends on:
Metabolizer status — poor metabolizers often plateau at 250-300 mcg.
Injury severity — acute injuries respond at lower doses than chronic conditions.
Route — oral requires roughly 2x injection dose.
Stacking — reduce if combining with TB-500 (CYP3A4 competition).
What are the most common BPC-157 dosing mistakes?
How a Genetic Report Changes Dosing
A pharmacogenomic test that includes CYP2D6, CYP3A4, CYP2C19, and NOS3 variants gives you three things a standard dosing guide can't:
- Metabolizer phenotype: Where you fall on the poor-to-ultrarapid spectrum, so you know whether to start low, go standard, or consider higher doses
- Drug interaction risk: Whether your current medications compete with BPC-157 for the same metabolic pathways
- Vascular sensitivity: Whether your NOS3 variants suggest starting with extra caution on the assessment dose
This doesn't replace working with a qualified practitioner. It gives both you and your practitioner better data to work with — instead of starting from population averages and hoping you're average.
Standard BPC-157 dosing is a starting point, not a protocol.
Your CYP3A4 status, drug interactions, and NOS3 variants determine where in the 200-500 mcg range you should actually be. A genetic report replaces guessing with data — so you start at the right dose for your biology, not the average dose for everyone.
Your genetics affect your peptide response.
Find out which peptides align with your DNA before you start any protocol.
Frequently asked questions
What is the standard BPC-157 dosage?
The most commonly used range is 250-500 mcg per day via subcutaneous injection, typically in 4-8 week cycles. For oral administration (capsules), the range is 500-1000 mcg/day due to lower bioavailability. However, these are population averages — your optimal dose depends on your CYP enzyme metabolism, body weight, injury severity, and whether you're stacking with other peptides.
How do CYP enzymes affect BPC-157 dosing?
CYP3A4 and CYP2D6 are the primary enzymes involved in BPC-157 clearance. Poor metabolizers (~5-10% of people) clear BPC-157 more slowly, meaning the standard dose produces higher tissue levels — they may need to start lower (200-250 mcg). Ultra-rapid metabolizers clear it faster and may need the higher end of the range. A pharmacogenomic test identifies your metabolizer status.
Should I start with a low dose of BPC-157?
Yes. Starting with an assessment dose of 150-200 mcg/day for the first week is recommended regardless of your target dose. This lets you evaluate tolerance, injection site reactions, and vascular effects before increasing. This is especially important if you're a poor CYP metabolizer or carry NOS3 gene variants affecting nitric oxide production.
Can I take BPC-157 orally instead of injection?
Yes, oral BPC-157 (capsules) is available and commonly used for gut-related conditions like ulcers, IBD, and NSAID-induced damage. Oral bioavailability is significantly lower than injection, so doses are typically doubled (500-1000 mcg/day vs 250-500 mcg for injection). For localized injury healing, injection near the injury site remains more effective.
How long should a BPC-157 cycle last?
Most protocols use 4-8 week cycles with 2-4 weeks off between cycles. Acute injuries often respond within 4 weeks. Chronic conditions or severe tissue damage may require the full 8 weeks. There's limited data on long-term continuous use, so cycling is the conservative approach.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.